The effectiveness of the BNT162b2 and ChAdOx1 vaccines against new severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infections requires continuous re …

The effectiveness of COVID-19 vaccination in preventing new severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infections in the general community is still unclear …

In the past few months, the results of several phase 3 studies showing high vaccine efficacy
against SARS-CoV-2 and the subsequent rapid regulatory approval and roll-out of several …

Abstract Background The B. 1.617. 2 (delta) variant of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19) …

Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2), the virus that causes coronavirus disease 2019 (Covid-19), have been used since …

To the Editor—On 4 August 2021, Tedros Adhanom Ghebreyesus, Director-General of the
World Health Organization, called for a global moratorium on booster doses of vaccination …

Background Assessment of the safety and efficacy of vaccines against the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is …

Currently approved viral vector-based and mRNA-based vaccine approaches against
coronavirus disease 2019 (COVID-19) consider only homologous prime-boost vaccination …

Six months ago, Miles Davenport and his colleagues made a bold prediction. On the basis of
published results from vaccine trials and other data sources, they estimated that people …

Background Reports have suggested that the efficacy of vaccines against COVID-19 might
have fallen since the delta (B. 1.617. 2) SARS-CoV-2 variant replaced the alpha (B. 1.1. 7) …